The US Food and Drug Administration’s high biosimilar approval standards appear to have streamlined its ability to deem all of the products interchangeable, should Congress enact the necessary legislation.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?